Scarica l'app Stockscreener
39.54
0.25%
0.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Precedente Chiudi:
$39.44
Aprire:
$39.37
Volume 24 ore:
2.06M
Relative Volume:
1.22
Capitalizzazione di mercato:
$7.37B
Reddito:
$29.52M
Utile/perdita netta:
$-567.06M
Rapporto P/E:
-10.80
EPS:
-3.66
Flusso di cassa netto:
$-551.11M
1 W Prestazione:
-2.18%
1M Prestazione:
+9.23%
6M Prestazione:
-28.28%
1 anno Prestazione:
+1.41%
Intervallo 1D:
$38.92
$40.05
Intervallo di 1 settimana:
$38.92
$42.60
Portata 52W:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Nome
Revolution Medicines Inc
Settore
Industria
Telefono
415-766-3638
Indirizzo
700 SAGINAW DR, REDWOOD CITY, CA
Confronta RVMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
39.54 | 7.53B | 29.52M | -567.06M | -551.11M | -3.66 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-16 | Reiterato | Needham | Buy |
| 2024-07-12 | Iniziato | Barclays | Overweight |
| 2024-07-08 | Iniziato | Jefferies | Buy |
| 2024-04-12 | Reiterato | Needham | Buy |
| 2024-04-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-04 | Iniziato | Wedbush | Outperform |
| 2023-11-16 | Iniziato | Raymond James | Outperform |
| 2023-02-28 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-10-21 | Iniziato | Oppenheimer | Outperform |
| 2022-05-20 | Iniziato | BofA Securities | Neutral |
| 2022-03-01 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-08-12 | Downgrade | Goldman | Buy → Neutral |
| 2021-05-18 | Iniziato | Goldman | Buy |
| 2020-05-21 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-09 | Iniziato | Cowen | Outperform |
| 2020-03-09 | Iniziato | Guggenheim | Buy |
| 2020-03-09 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial - Yahoo
Revolution Medicines begins phase 3 trial for lung cancer drug By Investing.com - Investing.com Canada
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer - BioSpace
Revolution Medicines (RVMD) Receives Adjusted Price Target from - GuruFocus
When (RVMD) Moves Investors should Listen - news.stocktradersdaily.com
Revolution Medicines (RVMD) Initiates RASolve 301 Phase 3 Trial - GuruFocus
Revolution Medicines Announces First Patient Dosed in Phase - GlobeNewswire
Revolution Medicines (RVMD) Price Target Reduced by H.C. Wainwri - GuruFocus
Revolution Medicines price target lowered to $72 from $73 at H.C. Wainwright - TipRanks
Revolution medicines outlines 2025 focus on RAS(ON) inhibitors in key cancer trials - MSN
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - Yahoo Finance
We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth - Yahoo Finance
Revolution’s KRAS drugs appear competitive in several lung cancer settings - Endpoints News
Revolution Medicines’ Earnings Call: Optimism Amid Rising Costs - TipRanks
RVMD: Guggenheim Maintains Buy Rating, Lowers Price Target to $8 - GuruFocus
The Lustgarten Foundation Honors Revolution Medicines for Transformative Research in Pancreatic Cancer - PRWeb
Oppenheimer Raises Price Target for RVMD, Maintains Outperform Rating | RVMD Stock News - GuruFocus
RVMD: Guggenheim Maintains Buy Rating, Lowers Price Target to $80 | RVMD Stock News - GuruFocus
RVMD Price Target Lowered but Buy Rating Maintained by Guggenheim | RVMD Stock News - GuruFocus
Revolution Medicines (RVMD) Target Price Raised Amid Positive Ou - GuruFocus
Revolution Medicines (RVMD) Target Price Raised Amid Positive Outlook | RVMD Stock News - GuruFocus
Needham Reiterates Buy Rating for Revolution Medicines (RVMD) | - GuruFocus
Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus
Revolution Medicines Reports Q1 2025 Financial Results - TipRanks
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus
Revolution Medicines Inc Reports Q1 2025 EPS of -$1.13 and Reven - GuruFocus
Earnings call transcript: Revolution Medicines sees stock surge after Q1 2025 update - Investing.com
Revolution Medicines Q1 2025 Earnings Call Transcript - MarketBeat
Revolution Medicines Q1 Net Loss Widens - marketscreener.com
Revolution Medicines (RVMD) Advances Key Clinical Trials and Strengthens Team | RVMD Stock News - GuruFocus
Revolution Medicines Inc Reports Q1 2025 EPS of -$1.13 and Revenue of $0.00 Million, Missing Estimates - GuruFocus
Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress - The Manila Times
Revolution Medicines patents new GTPase KRAS mutant inhibitors - BioWorld MedTech
(RVMD) Investment Report - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Regeneron (REGN) - The Globe and Mail
Revolution Medicines Inc [RVMD] Records 50-Day SMA of $37.82 - knoxdaily.com
Revolution Medicines Sets Date for Q1 2025 Financial Results: Key Updates Expected from RAS Cancer Pipeline - Stock Titan
Revolution Medicines, Inc. to Report Q1 2025 Financial Results on May 7, 2025 - Nasdaq
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 - GlobeNewswire
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? - AOL.com
Revolution Medicines’ (RVMD) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Revolution Medicines (RVMD) Reports Promising Data for Zoldonras - GuruFocus
A Guide To The Risks Of Investing In Revolution Medicines Inc (RVMD) - knoxdaily.com
Revolution Medicines Shares Rise on 'Encouraging' Phase 1 Lung Cancer Trial Data - marketscreener.com
Revolution’s Next KRAS Drug Shows Promise In NSCLC - insights.citeline.com
AACR 2025: Revolution has early stage KRAS success in NSCLC - BioWorld MedTech
Perhaps timely catching Revolution Medicines Inc (RVMD) would be a good idea - Sete News
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC - GuruFocus
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting | RVMD Stock News - GuruFocus
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting - The Manila Times
Revolution Medicines Inc Azioni (RVMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):